MiNA Therapeutics Limited, a London, UK-based provider of small activating RNA therapeutics, received a $15m equity investment from Eli Lilly and Company.
The company intends to use the funds to advance and expand its internal pipeline of saRNA therapeutics, which is initially focused on immuno-oncology and genetic diseases.
Led by Robert Habib, CEO, MiNA Therapeutics is the leader in small activating RNA therapeutics. Harnessing innate mechanisms of gene activation, small activating RNA therapeutics are a new class of medicines that can restore or boost normal function in patients’ cells. The company is advancing a proprietary pipeline of new medicines with an initial focus on cancer and genetic diseases, while collaborating with pharmaceutical companies to apply its technology platform across a broad range of therapeutic areas.
FinSMEs
12/07/2021